Locking-Domain Nanoparticle Vaccines for Stable Env Trimer Display
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing vaccine technologies face challenges in achieving effective and stable immunogenic responses, particularly for HIV-1 and other viral pathogens, due to issues with trimer yield, purity, and stability of Env proteins, and require complex purification methods.
Innovation Solution
Development of vaccine compositions with a polypeptide immunogen displayed on a self-assembling nanoparticle, stabilized by a locking domain embedded inside the nanoparticle, which forms a dimer through non-covalent interactions, and optionally includes a T-cell epitope and neck region to enhance stability and immunogenicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If traditional soluble trimers are used as vaccine immunogens, then the vaccine can be produced with simpler methods, but the immunogenicity is insufficient and requires prolonged immunization periods (6-12 months) to elicit tier-2 neutralizing antibody responses
Solution Approach 1:
The patent combines soluble trimers with nanoparticle carriers to create a composite vaccine formulation. The trimer immunogen (e.g., SOSIP or NFL) is displayed on the nanoparticle surface, merging the structural stability and immunogenicity of trimers with the adjuvant properties and antigen presentation capabilities of nanoparticles, thereby achieving both ease of manufacture and high immunogenicity
Solution Approach 2:
Nanoparticles serve as an intermediary carrier that enhances the immunogenicity of soluble trimers. The nanoparticle acts as a bridge between the trimer immunogen and the immune system, providing stable display of multiple trimers in a controlled geometry that facilitates B cell activation and neutralizing antibody production without requiring complex purification methods
2Stability of the object's composition
If Env proteins are stabilized and redesigned to form native-like trimers, then antigen stability is improved, but trimer yield and purity significantly decrease requiring complicated purification methods
Solution Approach 1:
The patent employs self-assembling nanoparticles that automatically organize into stable structures displaying multiple trimers. The nanoparticle-trimer complex self-assembles in solution without requiring complex purification steps to isolate stable trimers, as the nanoparticle framework inherently stabilizes the trimers in their native-like conformation while maintaining high yield
Solution Approach 2:
The nanoparticle carrier serves multiple functions simultaneously: it stabilizes the trimer immunogen, increases antigen density for B cell activation, provides a controlled display geometry, and eliminates the need for complicated purification methods. This multi-functionality resolves the contradiction between stability and productivity
3Reliability
If antigen density on nanoparticle surface is increased to enhance B cell activation, then immunogenicity is improved, but optimal spacing (5-10 nm between epitopes) becomes difficult to maintain
Solution Approach 1:
The patent divides the antigen display function across multiple nanoparticle subunits, each presenting a controlled number of trimers. By segmenting the antigen presentation across many identical subunits with fixed geometry, the system achieves high overall antigen density while maintaining precise inter-epitope spacing through the inherent structural regularity of the nanoparticle assembly
Solution Approach 2:
The patent optimizes the nanoparticle structure by adjusting parameters such as subunit composition, trimer attachment orientation, and nanoparticle size to achieve the desired epitope spacing of 5-10 nm. By changing these structural parameters during nanoparticle design and assembly, optimal spacing is maintained while achieving high antigen density for effective B cell activation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The vaccine compositions demonstrate enhanced stability, yield, and purity, eliciting robust tier-2 neutralizing antibody responses in animals within shorter timeframes, improving the effectiveness of HIV-1 vaccines.
Implementation Method 1
a locking domain that is embedded inside the nanoparticle and linked to subunit of the self-assembling nanoparticle. In these vaccine compositions, the locking domain is a protein subunit that can naturally form a dimer with another locking domain attached to a nearby nanoparticle subunit in solution through non-covalent interactions at the interface
Implementation Method 2
vaccine compositions containing (1) a polypeptide immunogen displayed on the surface of a self-assembling nanoparticle
Data Source
AI summary
The present invention provides novel nanoparticle presented vaccine compositions that are stabilized with a locking domain. Various immunogens can be employed in the preparation of the vaccine compositions, including viral immunogens such as HIV-1 and Ebola viral immunogens, and non-viral immunogens such as immunogens derived from bacteria, parasites and mammalian species. The invention also provides methods of using such vaccine compositions in various therapeutic applications, e.g., for preventing or treating viral infections.